Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Nosocomial Candida bloodstream infections rank among infections with highest mortality rates. A retrospective cohort analysis was conducted at Catholic University Hospital to estimate the risk factors for mortality of patients with candidemia. We reviewed records for patients with a Candida bloodstream infection over a 5-year period (January 2000 through December 2004). Two hundred ninety-four patients (42.1% male; mean age ± standard deviation, 65 ± 12 years) were studied. Patients most commonly were admitted with a surgical diagnosis (162 patients [55.1%]), had a central venous catheter (213 [72.4%]), cancer (118 [40.1%]), or diabetes (58 [19.7%]). One hundred fifty-four (52.3%) patients died within 30 days. Of 294 patients, 168 (57.1%) were infected by Candida albicans , 64 (21.7%) by Candida parapsilosis , 28 (9.5%) by Candida tropicalis , and 26 (8.8%) by Candida glabrata . When fungal isolates were tested for biofilm formation capacity, biofilm production was most commonly observed for isolates of C. tropicalis (20 of 28 patients [71.4%]), followed by C. glabrata (6 of 26 [23.1%]), C. albicans (38 of 168 [22.6%]), and C. parapsilosis (14 of 64 [21.8%]). Multivariable analysis identified inadequate antifungal therapy (odds ratio [OR], 2.35; 95% confidence interval [95% CI], 1.09 to 5.10; P = 0.03), infection with overall biofilm-forming Candida species (OR, 2.33; 95% CI, 1.26 to 4.30; P = 0.007), and Acute Physiology and Chronic Health Evaluation III scores (OR, 1.03; 95% CI, 1.01 to 1.15; P < 0.001) as independent predictors of mortality. Notably, if mortality was analyzed according to the different biofilm-forming Candida species studied, only infections caused by C. albicans ( P < 0.001) and C. parapsilosis ( P = 0.003) correlated with increased mortality. Together with well-established factors, Candida biofilm production was therefore shown to be associated with greater mortality of patients with candidemia, probably by preventing complete organism eradication from the blood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The multivariate analysis identified three factors associated with mortality: inadequate antifungal therapy, infection with biofilm-forming Candida species, and Apache III score.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
CDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Nosocomial Candida bloodstream infections (BSIs), with an estimated annual incidence in the United States of 6 to 10 candidemia episodes per 100,000 population, have become a considerable public health concern (24, 25, 29).”
BackgroundCDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
The APACHE III Prognostic System
Knaus, W. A., Wagner, D. P., Draper, E. A., Zimmerman, J. E., Bergner, M., Bastos, P. G., Sirio, C. A., Murphy, D. J., Lotring, T., Damiano, A., et al. (1991) · Chest · doi:10.1378/chest.100.6.1619 · Cited by 3,439
The APACHE III Prognostic System
Teres, D., & Lemeshow, S. (1992) · Chest · doi:10.1378/chest.102.6.1919b · Cited by 2,880
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 5×
“Of 294 patients with Candida BSIs (mean age standard deviation, 65 12 years; 42.1% male), 262 cases (89.1”
BackgroundInfluentialFriedman, N. D., Kaye, K. S., Stout, J. E., McGarry, S. A., Trivette, S. L., Briggs, J. P., Lamm, W., Clark, C., MacFarquhar, J., Walton, A. L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-10-200211190-00007 · Cited by 1,668
Manual of Clinical Microbiology, 7th ed.
Balows, A. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00102-9 · Cited by 1,613
Guidelines for the management of intravascular catheter-related infections
Mermel, L. A., Farr, B. M., Sherertz, R. J., Raad, I. I., O'Grady, N., Harris, J. S., & Craven, D. E. (2001) · Clinical Infectious Diseases · doi:10.1086/320001 · Cited by 1,449
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 4×
“Interestingly, two recent studies addressing the effects of delayed treatment for patients with candidemia found that receipt of an antifungal agent 24 h after the blood sample was obtained for culture was associated with an increased risk of mortality (6, 26).”
BackgroundResultInfluentialCandida biofilms and their role in infection
Douglas, L. J. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(02)00002-1 · Cited by 1,150
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Nosocomial Infections in Combined Medical-Surgical Intensive Care Units in the United States
Richards, M. J., Edwards, J. R., Culver, D. H., Gaynes, R. P., & System, N. N. I. S. (2000) · Infection Control & Hospital Epidemiology · doi:10.1086/501795 · Cited by 1,028
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784
Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms
Ramage, G., Vande Walle, K., Wickes, B. L., & López-Ribot, J. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2475-2479.2001 · Cited by 753
Ramage, G., Saville, S. P., Thomas, D. P., & López-Ribot, J. L. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.4.633-638.2005 · Cited by 678
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
The APACHE III Prognostic System
Knaus, W. A. (1992) · Chest · doi:10.1016/s0012-3692(16)40910-4 · Cited by 626
Biofilm formation by Candida species on the surface of catheter materials in vitro
Hawser, S. P., & Douglas, L. J. (1994) · Infection and Immunity · doi:10.1128/iai.62.3.915-921.1994 · Cited by 599 · cited 5×
“Candida species and strain type were shown to affect biofilm formation in vitro (3, 11, 19, 37).”
BackgroundInfluentialAlmirante, B., Rodríguez, D., Park, B. J., Cuenca-Estrella, M., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J., Gimenez, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1829-1835.2005 · Cited by 566
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Comparison of Biofilms Formed by Candidaalbicans and Candidaparapsilosis on Bioprosthetic Surfaces
Kuhn, D. M., Chandra, J., Mukherjee, P. K., & Ghannoum, M. A. (2002) · Infection and Immunity · doi:10.1128/iai.70.2.878-888.2002 · Cited by 485
Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000
Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M., Tauber, M. G., Pittet, D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380637 · Cited by 478 · cited 2×
“glabrata, which was the fourth most common species in our study but the second most common in Switzerland (22), the United Kingdom (15), and the United States (9).”
BackgroundMorgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437
Pfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423
Uses and Limitations of the XTT Assay in Studies of Candida Growth and Metabolism
Kuhn, D. M., Balkis, M., Chandra, J., Mukherjee, P. K., & Ghannoum, M. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.506-508.2003 · Cited by 339
Shin, J. H., Kee, S. J., Shin, M. G., Kim, S. H., Shin, D. H., Lee, S. K., Suh, S. P., & Ryang, D. W. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1244-1248.2002 · Cited by 334
Quantitative variation of biofilms among strains in natural populations of Candida albicans
Li, X., Yan, Z., & Xu, J. (2003) · Microbiology · doi:10.1099/mic.0.25932-0 · Cited by 304
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · cited 1×
“According to published criteria (27, 31), isolates were classified as susceptible, susceptible dose-dependent, or”
BackgroundJin, Y., Yip, H. K., Samaranayake, Y. H., Yau, J. Y., & Samaranayake, L. P. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.7.2961-2967.2003 · Cited by 254
Candida, Cryptococcus, and Other Yeasts of Medical Importance
Howell, S. A., & Hazen, K. C. (2011) · Manual of Clinical Microbiology · doi:10.1128/9781555816728.ch115 · Cited by 246
Kumamoto, C. A. (2002) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(02)00371-5 · Cited by 214
Management and outcome of bloodstream infections due to Candida species in England and Wales
Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J., & Wilson, J. A. (2003) · Journal of Hospital Infection · doi:10.1016/s0195-6701(03)00085-9 · Cited by 187 · cited 2×
“glabrata, which was the fourth most common species in our study but the second most common in Switzerland (22), the United Kingdom (15), and the United States (9).”
BackgroundGlobal trends in candidemia: Review of reports from 1995–2005
Morgan, J. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0044-7 · Cited by 139
Epidemiology and Prognostic Determinants of Bloodstream Infections in Surgical Intensive Care
Harbarth, S. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.12.1353 · Cited by 135
Biofilm Formation by and Antifungal Susceptibility of Candida Isolates from Urine
Jain, N., Kohli, R., Cook, E., Gialanella, P., Chang, T., & Fries, B. C. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.02439-06 · Cited by 131
Candidemia in French hospitals: incidence rates and characteristics
Richet, H., Roux, P., de Champs, C., Esnault, Y., & Andremont, A. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00446.x · Cited by 128
Tortorano, A. M., Biraghi, E., Astolfi, A., Ossi, C., Tejada, M., Farina, C., Perin, S., Bonaccorso, C., Cavanna, C., Raballo, A., et al. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2002.1261 · Cited by 116
Walsh, T. J., & Rex, J. H. (2002) · Clinical Infectious Diseases · doi:10.1086/338715 · Cited by 82
Risk factors for candidemia-related mortality at a medical center in central Taiwan.
Cheng, Y.-R., Lin, L., Young, T.-G., Liu, C.-E., Chen, C., & Tsay, R.-W. (2006) · PubMed · Cited by 59
Cited by
Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., Dodek, P., Wood, G., Kumar, A., Simon, D., et al. (2009) · Chest · doi:10.1378/chest.09-0087 · Cited by 1,187
Candida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Development and regulation of single- and multi-species Candida albicans biofilms
Lohse, M. B., Gulati, M., Johnson, A. D., & Nobile, C. J. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.107 · Cited by 643
Ramage, G., Rajendran, R., Sherry, L., & Williams, C. (2012) · International Journal of Microbiology · doi:10.1155/2012/528521 · Cited by 583
Our Current Understanding of Fungal Biofilms
Ramage, G., Mowat, E., Jones, B., Williams, C., & Lopez-Ribot, J. (2009) · Critical Reviews in Microbiology · doi:10.3109/10408410903241436 · Cited by 483
Metadata
- Authors
- Tumbarello, M., Posteraro, B., Trecarichi, E. M., Fiori, B., Rossi, M., Porta, R., de Gaetano Donati, K., La Sorda, M., Spanu, T., Fadda, G., Cauda, R., & Sanguinetti, M.
- Affiliations
- Institutes of Infectious Diseases
- Università Cattolica del Sacro Cuore (IT)
- Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2007-06
- Volume
- 45
- Issue
- 6
- Pages
- 1843-1850
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC1933062
- OpenAlex
- W1976891952
- Cited by
- 343
- References
- 46
- Citations by year
- 2026: 15 · 2025: 9 · 2024: 9 · 2023: 12 · 2022: 12 · 2021: 23 · 2020: 21 · 2019: 14 · 2018: 19 · 2017: 27 · 2016: 25 · 2015: 20 · 2014: 23 · 2013: 24 · 2012: 22
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, mortality risk factors, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida glabrata, APACHE III score, nosocomial bloodstream infection, central venous catheters, antifungal susceptibility testing, Candida parapsilosis complex
- MeSH terms
- Aged, Antifungal Agents, Candida, Candidiasis, Female, Hospitals, University, Humans, Italy, Male, Microbial Sensitivity Tests, Middle Aged, Predictive Value of Tests, Risk Factors, Fungemia, Biofilms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.